After immunogenic challenge, infiltrating and dividing lymphocytes markedly increase lymph node cellularity, leading to organ expansion 1, 2 .
Here we report that the physical elasticity of lymph nodes is maintained in part by podoplanin (PDPN) signalling in stromal fibroblastic reticular cells (FRCs) and its modulation by CLEC-2 expressed on dendritic cells. We show in mouse cells that PDPN induces actomyosin contractility in FRCs via activation of RhoA/C and downstream Rho-associated protein kinase (ROCK). Engagement by CLEC-2 causes PDPN clustering and rapidly uncouples PDPN from RhoA/C activation, relaxing the actomyosin cytoskeleton and permitting FRC stretching. Notably, administration of CLEC-2 protein to immunized mice augments lymph node expansion. In contrast, lymph node expansion is significantly constrained in mice selectively lacking CLEC-2 expression in dendritic cells. Thus, the same dendritic cells that initiate immunity by presenting antigens to T lymphocytes 3 also initiate remodelling of lymph nodes by delivering CLEC-2 to FRCs. CLEC-2 modulation of PDPN signalling permits FRC network stretching and allows for the rapid lymph node expansion-driven by lymphocyte influx and proliferation-that is the critical hallmark of adaptive immunity.
Lymph nodes are meeting places for T lymphocytes and antigenpresenting dendritic cells 1, 2 . T-cell-dendritic-cell interactions are supported by FRCs 4,5 , a complex interconnected network that produces and ensheathes extracellular matrix components 6 that filter draining lymph 7 . FRC networks additionally provide physical routes for leukocyte traffic 1 , and chemoattractants for T cells and dendritic cells 5 . Furthermore, contact with FRCs promotes chemokinesis in dendritic cells, facilitating their migration within lymph nodes 8 . This is partly due to cytoskeletal changes in dendritic cells induced upon signalling by the C-type lectin receptor CLEC-2 when it is engaged by PDPN expressed on FRCs 8 . We asked whether, in addition to working as a PDPN receptor and promoting dendritic cell movement along FRCs, CLEC-2 might also act as a ligand, modulating PDPN function and altering the properties of the FRC network.
To examine PDPN signalling in fibroblasts, wild-type PDPN tagged with cyan fluorescent protein (CFP) was overexpressed in NIH/3T3 cells, which express only low levels of the endogenous protein 8 . Within 30 h of transfection, CFP was detectable at the plasma membrane, where it co-localized with mCherry-tagged ezrin, consistent with reports of a direct interaction between the two proteins 9,10 ( Fig. 1a and Supplementary Video 1). Ezrin belongs to a family of closely related proteins, ezrin, radixin and moesin (ERM), which tether the actin cytoskeleton to the plasma membrane. We therefore examined the localization and phosphorylation of ERM proteins, along with myosin light chain (MLC), which mediates actin-dependent contraction, in PDPN-CFP-overexpressing cells. In contrast to untransfected cells, PDPN-CFP 1 NIH/3T3 cells displayed phosphorylated (p)ERM and pMLC accumulation at the cell cortex ( Fig. 1a ) and often rounded up, features typical of contractile cells [11] [12] [13] [14] . A non-phosphorylatable ezrin T567A mutant formally demonstrated the key role of ERM phosphorylation in PDPN-driven cell contraction ( Fig. 1b) .
To determine which pathways connected PDPN to cell contraction, a chemical screen was conducted, which revealed relaxation upon inhibition of RhoA/C, ROCK or myosin II family proteins (Extended Data Fig. 1a, b ). Strikingly, treatment with soluble recombinant CLEC-2-Fc protein phenocopied RhoA/C and ROCK inhibition, almost completely reversing the contraction induced by PDPN-CFP (Fig. 1c ). The inhibition by CLEC-2 was rapid but transient ( Fig. 1c ) and led to ezrin redistribution from the plasma membrane to the cytoplasm (Fig. 1d ). To test this in FRCs expressing physiological levels of PDPN, we generated lymph node FRC lines (Extended Data Fig. 2 and Methods). Sublines stably expressing fluorescence resonance energy transfer (FRET) biosensors reporting RhoA or Rac1 activity were exposed to CLEC-2-Fc-coated 10 mm beads. In agreement with the NIH/3T3 studies, RhoA activity was immediately and robustly reduced when CLEC-2 beads made contact with FRCs ( Fig. 1e and Supplementary Video 2). Sudden loss of RhoA activity was also evident from temporary loss of adhesion 15 (Supplementary Videos 2 and 3). In contrast, Rac1 activity gradually increased after exposure to CLEC-2 beads ( Fig. 1e and Supplementary Video 3), which was confirmed in longer-term experiments by pulldown of GTPbound Rac1 (Fig. 1f ). Higher Rac1-GTP levels increased ARP2/3 1 lamelipodial protrusions, and tail retraction defects were also observed in FRCs when PDPN was stably depleted (PDPN knockdown FRCs; Fig. 1f and Extended Data Fig. 3 ). To identify guanine-nucleotide exchange factors (GEFs) that could connect PDPN to activation of RhoA/C, we decreased the expression of candidates using short interfering RNA (siRNA) and found that PDPN-induced contractility primarily requires GEF-H1 in NIH/3T3 and FRCs (Extended Data Fig. 1c, d ). We also looked for further changes in FRCs consistent with decreased RhoA/C activity and found that PDPN knockdown or engagement by CLEC-2 caused rapid dissolution of stress fibres ( Fig. 1g , Supplementary Video 4 and Extended Data Figs 3, 4) . Thus, PDPN in fibroblasts associates with ezrin and signals to promote RhoA/C-dependent actomyosin-driven contraction. This is alleviated by CLEC-2 engagement, causing uncoupling of PDPN from ezrin and a RhoA/C to Rac1 switch. We hypothesize that Rac1 activity is increased indirectly as a consequence of reduced RhoA/C activity 14, 16 .
The cytoplasmic tail of PDPN undergoes phosphorylation and ezrin recruitment requires basic residues surrounding Ser 167 (refs 10, 17) . We therefore tested whether phosphorylation of Ser 167 controlled PDPNinduced contractility. Overexpression of the PDPN(S167A) mutant failed to cause contraction in NIH/3T3 fibroblasts and occasionally caused collapse of the cytoskeleton, potentially by inhibiting activity of low levels of endogenous PDPN ( Fig. 2a) . In contrast, a PDPN(S167E) phosphomimetic mutant induced contractility comparable to the wild-type protein ( Fig. 2a, b ). Inhibition of ROCK blocked contraction by both wild-type and S167E PDPN ( Fig. 2b) , placing ROCK activity downstream of Ser 167 phosphorylation. However, CLEC-2-Fc treatment, although inhibiting contraction induced by wild-type PDPN, had no effect on S167E PDPN ( Fig. 2b ), suggesting that regulation of the phosphorylation status of Ser 167 is one mechanism by which CLEC-2 uncouples PDPN from actomyosin contractility.
We considered how FRCs express high levels of endogenous PDPN, yet, unlike transfected NIH/3T3 cells, do not display hypercontractility. As PDPN remained at the plasma membrane when engaged with CLEC-2 ( Fig. 1d ), we hypothesized that it partitions between active and inactive pools, the latter being maintained by binding to an inhibitory partner such as CD44 (refs 18, 19) . FRCs express high levels of both PDPN and CD44 (ref. 4 ) and knockdown of PDPN led to a concordant reduction of CD44 ( Fig. 2c ), suggesting an interaction. NIH/3T3 cells express low levels of CD44, perhaps accounting for their susceptibility to contraction after overexpression of PDPN. Consistent with that notion, co-transfection of CD44 and PDPN into NIH/3T3 fibroblasts markedly inhibited contraction ( Fig. 2d ).
CD44 resides within cholesterol-rich lipid rafts 19 and we tested whether CLEC-2 induces PDPN redistribution to such rafts. In steady-state FRCs, PDPN and lipid rafts were found in small, partially co-localized clusters ( Fig. 2e ), as described in epithelial cells 19 . CLEC-2-Fc treatment induced formation of larger clusters in which PDPN and lipid rafts were more often co-localized ( Fig. 2e ). Notably, depletion of cholesterol from FRC membranes with methyl-b-cyclodextrin (MbCD) increased contractility, which was prevented by PDPN knockdown (Fig. 2f ). CLEC-2 no longer inhibited PDPN-induced contraction in NIH/3T3 cells pre-treated with MbCD ( Fig. 2g ). Together, these data support the notion that CLEC-2 sequesters PDPN within lipid rafts, where increased interaction with CD44 prevents signalling to RhoA/C. Interestingly, CD44 can itself also drive contractility when excluded from lipid rafts (data not shown), suggesting a mutually inhibitory interaction with PDPN.
To explore the biological significance of PDPN-CLEC-2 interactions for FRC function, we examined cell behaviour in three-dimensional collagen gels. Notably, FRCs reorganized the gel matrix to occupy a smaller volume, and this was inhibited by CLEC-2 treatment or PDPN knockdown ( Fig. 3a ). Furthermore, CLEC-2 treatment or PDPN knockdown 
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caused marked elongation of FRCs in three-dimensional culture ( Fig. 3b and Extended Data Fig. 5 ). To determine the relevance of FRC stretching for lymph node dynamics, we investigated FRC network changes after induction of inflammation in vivo, which leads to upregulation of CLEC-2 by both lymph-node-resident and migratory dendritic cells 8, 20 . We first examined the cellular composition of draining lymph nodes after subcutaneous immunization of mice with ovalbumin (OVA) in complete Freund's adjuvant (CFA). During the afferent phase (days 0-6), T-and B-cell numbers increased rapidly and total lymph node cellularity augmented 2-3 fold (Extended Data Fig. 6 ). However, numbers of FRCs (CD45 2 PDPN 1 CD31 2 ) remained constant until day 6 ( Fig. 3c ). This lag in FRC proliferation has been previously observed 21 , although the kinetics probably depend on the type and strength of the inflammatory stimulus. In contrast, blood endothelial cells (CD45 2 PDPN 2 CD31 1 ), a distinct lymph node stromal population, increased in number from the earliest time point (Extended Data Fig. 6 ). If FRCs do not proliferate during the early stages of acute inflammation, then to accommodate increased lymph node size the FRC network needs to 'stretch' to avoid disruption 21 . Consistent with that, the mean forward scatter of lymph node FRCs, an indication of cell size, increased after immunization (Fig. 3d ) 21 and the integrity of the FRC network was maintained ( Fig. 3e) . A gap analysis algorithm 22 revealed significantly larger spaces between the reticular network branches after immunization, consistent with FRC stretching (Fig. 3f ). In a complementary approach, we used PDGFRaKI-H2B-GFP mice (Extended Data Fig. 7 ) and calculated the spacing between FRC nuclei (GFP 1 ) using automated morphometric analysis software, which confirmed that FRCs spread further apart after immunization ( Fig. 3g ). Together, these data indicate that FRCs expand and that the pre-existing FRC network enlarges in response to acute inflammation such as that following immunization.
The profound cytoskeletal changes in FRCs after CLEC-2 binding in vitro suggested that inhibition of PDPN-induced contractility by CLEC-2 1 dendritic cells might aid FRC network enlargement in vivo. Consistent with this, lymph node influx of immigrant dendritic cells (CD45 1 CD11c 1 MHCII hi ) bearing high CLEC-2 levels 8 peaked at day 2 after OVA/CFA immunization ( Fig. 3c ). We therefore examined lymph node architecture and expansion in Cd11c-cre 3 Clec1b fl/fl mice (CD11c DCLEC-2 ). These mice display selective ablation of CLEC-2 in CD11c 1 cells (Extended Data Fig. 8 ), the majority of which within the T-cell zone are dendritic cells. Interestingly, in .24-week-old CD11c DCLEC-2 mice, steady-state lymph node size was significantly reduced compared with controls ( Fig. 4a ), which was not the case in younger mice ( Fig. 4b ; non-draining lymph node). However, after immunization, expansion of draining lymph nodes was attenuated and spaces within the FRC network were smaller in young CD11c DCLEC-2 mice compared with controls ( Fig. 4b, c ). Finally, the lymph nodes of CD11c DCLEC-2 mice remained more rigid and less deformable than controls after immunization (Fig. 4d) .
The attenuated expansion of lymph nodes in CD11c DCLEC-2 mice could be due to reduced numbers of immigrating dendritic cells, decreasing antigen availability and limiting T-cell expansion. However, similar results were obtained upon administration of incomplete Freund's adjuvant without OVA or mycobacterial antigens (data not shown). Moreover, treatment by subcutaneous injection of recombinant CLEC-2-Fc protein but not a control Fc reagent (data not shown) after CFA/OVA S167A S167E 
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immunization markedly augmented lymph node expansion ( Fig. 4e ) and, importantly, completely rescued defects in lymph node expansion in CD11c DCLEC-2 mice (Fig. 4e ). The restoration of lymph node expansion indicates that diminished CLEC-2 provision rather than a dearth of immigrant antigen-presenting dendritic cells limits such expansion in CD11c DCLEC-2 mice. Together, these data indicate that CLEC-2 delivery by dendritic cells is required for maintaining FRC network architecture in vivo and is permissive for acute increases in lymph node size driven by cell influx provoked by local inflammation. Lymph nodes are dynamic structures that must rapidly expand to accommodate leukocyte recruitment and proliferation. Given that lymph 
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nodes can expand tenfold during adaptive immune responses while maintaining integrity, stromal components must by necessity proliferate 21, 23 . However, in the early phases of adaptive immune responses or in response to acute inflammation, FRC proliferation is insufficient to account for lymph node expansion 21 (Fig. 3b ). We show that early lymph node expansion is permitted by FRC network relaxation, induced by increased availability of CLEC-2 hi dendritic cells. We previously reported that CLEC-2 engagement by PDPN promotes dendritic cell migration along the FRC network 8 . Our data now show that PDPN is not simply a ligand for CLEC-2 but that it also reverse signals into FRCs to control actomyosin contractility. Our results suggest that a function of endogenous PDPN on FRCs is to cause stromal network contraction and create physical tension in lymph nodes. This is offset by constant contact between FRCs and CLEC2 1 resident dendritic cells, balancing contractility and controlling lymph node cellularity. The influx of additional CLEC-2 hi dendritic cells, combined with the upregulation of CLEC-2 on resident dendritic cells during acute inflammation 8, 20 , increases inhibition of PDPN, allowing the FRC network to stretch. We predict that this same mechanism can promote lymph node reduction as the short wave of increased CLEC-2 availability ends and PDPN activity returns. Whether the underlying collagen network is similarly elastic and to what extent it acts to limit or promote lymph node expansion is an as yet unaddressed question. Interestingly, CLEC-2 may not be sufficient for sustained lymph node expansion, as administration of CLEC-2-Fc in the absence of inflammation did not affect lymph node size. Rather, CLEC-2 inhibition of PDPN is permissive for stretching and the influx of leukocytes via the high endothelial venules and afferent lymph probably provides the force for expansion. It is interesting to speculate that the stretching mechanism described in this study may also help initiate subsequent FRC proliferation, given the emerging connections between tension and cell cycle regulation 24 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
Mice. Experiments were performed in accordance with national and institutional guidelines for animal care and approved by the Institutional Animal Ethics Committee Review Board, Cancer Research UK and the UK Home Office. Wild-type C57BL/6J mice were purchased from Charles River Laboratories. PDGFRaKI-H2B-GFP mice (B6.129S4-Pdgfratm11(EGFP)Sor/J) were purchased from Jackson Laboratories. To generate CLEC-2 floxed mice on a C57BL/6 background, C57BL/6 mouse Clec1b genomic regions were cloned into a pFloxRI1TK targeting vector from the bacterial artificial chromosome (BAC) clone R248K14 using the Red/Et recombination of Quick and Easy BAC modification kit (Gene Bridges). Primers used were: Clec1b BAC Fwd, TATTACCTGATGCTGTTACATCTCAGCTCTGCAG TATTTAGCCACCTTAGAGTTCCTAGCTGCTGACTCTgggtaccgagctcgaattct accg; Clec1b BAC Rev, CTGGGTTCTTTCCAGCTTCTGGCTATTATAAATAA GGCTGTTATGAACATAGTGGAGCATGTGTCCTTCTTgcggccgccaccgcggtgg agctcca. Uppercase letters indicate regions homologous to Clec1b regions and lowercase letters indicate regions homologous to pFloxRI1TK vector. PCR was performed using Pwo DNA polymerase (Roche) following the manufacturer's instructions.
The 59 loxP site was introduced in the intronic region between exon 1 and exon 2 by insertion of the loxP-pgk-gb2-NEO-loxP cassette (Gene Bridges) using the following primers: 1st loxP Fwd, AAAACCCAAAACCAAAAAACCAAAACCAAC AACAAAACAAAAAAACAGATaattaaccctcactaaagggcg; 1st loxP Rev, ACTTAT TCTCTGTCCATTCTAACATATAACTGGCTACCAAGGCCACGTGTtaatacg actcactatagggctc. Uppercase letters indicate regions homologous to Clec1b regions and lowercase letters indicate regions homologous to loxP-pgk-gb2-NEO-loxP cassette. PCR was performed using Pwo DNA polymerase (Roche) following the manufacturer's instructions.
The vector was then transformed into Cre-expressing Escherichia coli EL350 (gift from A. Behrens), leading to recombination of the cassette and leaving a single loxP site.
Next, the FRT-pgk-gb2-NEO-FRT-loxP cassette was introduced into the intronic region between exon 4 and exon 5 using the following primers: Rb2 Fwd, tcccatgtc aagcattttggaatgctgaggggaaacattgaaatgctgttaattaaccctcactaaagggc; Rb2 Rev, tctcagag gagcacacagtgcaaaccattaagaaacacatgaaaaggaaataatacgactcactatagggctcg. Uppercase letters indicate regions homologous to Clec1b regions and lowercase letters represent regions homologous to FRT-pgk-gb2-NEO-FRT-loxP cassette. PCR was performed using Pwo DNA polymerase (Roche) following the manufacturer's instructions.
The targeting vector was linearized by SfiI digestion (New England Biolabs), precipitated by phenol/chloroform and electroporated into PRX-B6N C57BL/6N embryonic stem (ES) cells.
Screening for homologous recombination in ES cells and mice was done by PCR using primers inside the FRT-pgk-gb2-NEO-FRT-loxP and outside the homology arm: Clec1b Gen Rev, agaccctgagaaggctgga; NEO 39 sense, gctcccgattcgcagcgcatc.
Deletion of the NEO cassette was performed by crossing Clec1b-targeted mice with b-actin-Flp (B6.Cg-Tg(ACTFLPe)9205Dym), and thereafter generating Clec1b fl/fl by interbreeding and screening for deletion of the NEO cassette using the following primers: Seq FRT Fwd, cctggtaaggagggtcccat; Seq FRT Rev, atgagtctgctagggatgct.
Generation of CD11c DCLEC-2 was achieved by crossing Clec1b fl/fl with CD11c-Cre mice (B6.Cg-Tg(Itgax-cre)1.1Reiz; gift from B. Reizis). Both males and females were used for in vivo experiments and were aged 8-12 weeks unless otherwise stated in figures. Cre-negative littermates were used as controls in all experiments. qPCR analysis of Clec1b messenger RNA. CD11c 1 cells from day 9 cultures of bone marrow in granulocyte-macrophage colony stimulating factor (GM-CSF) (bone marrow dendritic cells and treated with lipopolysaccharide (LPS) for 6 h or from spleens were enriched by MACS using CD11c beads (Miltenyi). RNA was extracted using an RNeasy mini kit (Qiagen) and cDNA generated using Superscript II reverse transcriptase (Invitrogen). qPCR was carried out using Sybr Green comparing Clec1b expression to GAPDH in each sample. Primers for Clec1b: Fwd, TTTGAGCACAAGTGCAGCCCC; Rev, AAGCAGTTGGTCCACTCTTG. Constructs. PDPN-CFP was as previously described 8 . RhoA and Rac1 FRET biosensors were provided by M. Matsuda 25 . GFP-MLC was as previously described 12 . PDPN wild type and S167A and S167E mutants were cloned into pcDNA3.1-V5-His by PCR using EcoR1 and NotI restriction sites. Cell lines. NIH/3T3 fibroblasts were cultured in DMEM plus glucose (Life Technologies, Invitrogen) with 10% fetal bovine serum (FBS) and penicillin and streptomycin (PS). Cells were incubated and maintained at 37 uC in 5% CO 2 . Mouse lymph node FRC lines were generated by first digesting skin-draining lymph nodes from C57BL/6 mice and then culturing adherent stromal cells as previously reported 8 . On day 4, stromal cells were immortalized by infection with HPV-E6-encoding retrovirus and selected with 2.5 mM puromycin as for the generation of carcinomaassociated fibroblast cell lines 26 . Immortalized FRCs were isolated by sequential MACS depletion of CD45 1 and CD31 1 cells using biotin-conjugated antibodies and anti-biotin beads (Mitenyi). FRC cell lines and maintained in DMEM plus glucose (Life Technologies, Invitrogen) with 10% FBS, PS and 1% Insulin-Transferrin-Selenium (Life Technologies, Invitrogen) at 37 uC in 5% CO 2 , and split using cell dissociation buffer (Life Technologies, Invitrogen). Stable knockdown of PDPN in FRCs was achieved with two different short hairpin (sh)RNA lentiviruses obtained from The RNAi Consortium of the Broad Institute that targeted the following sequences: GCTGCATCTTTCTGGATAATA (PDPN KD1) and GTTCTCCCAA CACATCTGAAA (PDPN KD2). FRC cell lines expressing RhoA or Rac1 biosensors were generated by co-transfection of the biosensor plasmid with PiggyBac transferase using lipofectamine 2000, followed by selection with 5 mM blasticidin for 2 weeks. GFP-MLC-expressing FRC cell lines were generated by lentiviral transduction and cell sorting. All cell lines were regularly tested for absence of mycoplasma contamination by the Cell Services Laboratory, Cancer Research UK London Research institute. Overexpression studies. NIH/3T3 cells were plated at a density of 50,000 cells ml 21 in a glass-bottomed 24-well plate (MatTek) the day before transfection with plasmids encoding GFP, PDPN-CFP or PDPN-V5-His using Effectene transfection reagent (Qiagen) as per supplier's instructions. After 24 h, cells were treated with chemical inhibitors at the concentrations indicated (see Extended Data Fig. 1b ) for 6 h before fixation. CLEC-2-Fc was added at 10 mg ml 21 for the time indicated in figures before fixation. In co-transfection experiments, plasmids encoding PDPN-CFP and ezrin-mCherry or PDPN-V5-His and CD44-GFP were added in equal amounts to the transfection mix. The cells were analysed by fluorescence microscope (320, Nikon Eclipse Te2000-S) and contraction status scored manually. Cells were grouped into either contracted, partially contracted, spread or collapsed, depending on their morphology. High-resolution images were taken using a confocal microscope (Zeiss 710 using a 320/0.8NA objective). siRNA knockdown of RhoGEFs. siRNA smartpools containing the following sequenences were obtained from Dharmacon. NIH/3T3 cells or FRC cell lines were transfected using Dharmafect reagent 2 according to the manufacturer's instructions. Mcf2 (Dbl), UGAUCAGUCUCCCAAAUUG; CCAUGCCUUUCAUCAA UUA; GGUGAUAACCGCAAAUUUG; CAAAGUGCAUAGACUCUUA; GEF-H1 (AHRGEF2), CAACAUUGCUGGACAUUUC; GCACUGGGAUGCUGGA AGA; GUACCAAGGUCAAGCAGAA; UGGAAUCCCUUAUUGAUGA; LARG (ARHGEF12), GAUCAAGUCUCGCCAGAAA; GGACGGAGCUGUAAUUG CA; GAAAGGAGUUCCACAAUGC; GAAAGGAGUUCCACAAUGC; p115 rhogef (ARHGEF1), GGUGUAACCUCAUCACUGA; GGAAAGACCGAGGC AACUA; GGCAAGAGGUCAUCAGCGA; GGGCUGAGCAGUAUCCUAG. Immunofluorescence staining. Cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min before permeabilization in PBS containing 0.2% Triton-X for 10 min at room temperature. The cells were stained with 49,6-diamidino-2-phenylindole (DAPI; Sigma, d9542) to reveal DNA in cell nuclei and tetramethylrhodamine (TRITC)-phalloidin (Sigma, p1951) to reveal F-actin in 3% bovine serum albumin with PBS plus 0.1% Tween-20. Cells were stained using anti-pMLC (S19) (Cell Signaling Technology #3675) or anti-pERM antibody (Cell Signaling Technology #3141) followed by appropriate Alexafluor-conjugated secondary antibodies (Invitrogen). PDPN-V5 was stained using anti-V5 fluorescein isothiocyanate (FITC)conjugated antibody (Invitrogen R963-25). ARP2/3 was stained using anti-p34-Arc/ ARPC2 antibody (07-227 Millipore). Lipid raft co-localization analysis. Lipid raft labelling was carried out on ice on unfixed cells according to manufacturer's instructions (Vybrant lipid raft labelling kit 555, Invitrogen). Cells were then fixed in 4% paraformaldehyde before staining for PDPN (8.1.1 AF660-conjugated; eBioscience 50-5381-80). Confocal immunofluorescence images (363/1.4NA oil immersion objective) of FRCs plated on glass either untreated or treated with 10 mg ml 21 CLEC-2-Fc for 30 min before staining were analysed using Zen image analysis software (Zeiss). The correlation coefficient R was calculated based on pixel intensity. CLEC-2-Fc treatment in vitro. Generation of CLEC-2-Fc was as previously described 8 . Soluble CLEC-2 was used at 10 mg ml 21 diluted in cell culture medium. For CLEC-2-beads, 10 mm protein A-coated microspheres (Bangs laboratories) were incubated with 100 mg ml 21 CLEC-2-Fc diluted in PBS for 1 h at 4 uC then washed with cell culture medium. CLEC-2-Fc or CLEC-2-beads were added for the time indicated in the figures before fixation. Lymph node expansion in vivo. Mice were immunized with 100 ml of an emulsion of OVA in CFA (100 mg OVA per mouse) or PBS in incomplete Freund's adjuvant (IFA) subcutaneously in the right flank. Draining inguinal lymph nodes were taken for analysis at the indicated days after immunization; left-side nondraining lymph nodes were taken for comparison. Where mice were treated with CLEC-2-Fc, they received 10 ml (1 mg in PBS) subcutaneously adjacent to site of immunization on days 1 and 3. Lymph nodes were first weighed, then digested as previously described 27 . Cells were counted and stained for flow cytometry analysis. Alternatively, intact lymph nodes were fixed in 10% formalin for immunohistochemistry analysis. Lymph node deformation assay. Draining and non-draining inguinal lymph nodes were taken from CD11c DCLEC-2 mice and littermate controls on day 5 after CFA immunization. Lymph nodes were placed on the contact points of a digimatic LETTER RESEARCH thickness gauge (Mitutoyo) and subjected to 1.4 N of applied force. Deformability was calculated as follows: Deformability 5 1 2 (lymph node size under 1.4 N/lymph node size before force was applied). Each lymph node was measured twice and the results averaged. Flow cytometry. Cells isolated from lymph nodes, FRCs or NIH/3T3 cell lines were suspended in FACS buffer (PBS 2% FCS, 2 mM EDTA) and first blocked with anti-CD16/CD32 (eBioscience) for all staining procedures. Cells were counted on a FACS Calibur by reference to fluorescence beads. Stained cells were analysed on either a FACS Calibur or LSRII. Antibodies used for staining: CD45.1 (BD Biosciences), CD140a (clone APA5 eBioscience), CD31 (BD Biosciences), PDPN (clone 8.1.1 eBioscience), CD35 (clone 8C12 BD Biosciences), VCAM-1 (clone M/K-2 Abcam), CD44 (clone IM7 BD Biosciences), CD3 (BD Biosciences), CD19 (clone ID3 BD Biosciences), MHCII (I-A/I-E BD Biosciences), CD11c (clone HL3 BD Biosciences). Immunohistochemistry. Tissue sections 4 mm thick were cut at three levels (with 150 mm between the levels) from formalin-fixed paraffin-embedded lymph nodes. These sections were then stained using the Vector ABC elite detection system (PK6100 1:250, Vector Laboratories). Slides were first incubated with a primary antibody for 1 h (anti-GFP: AB6673 1:350, Abcam; anti-PDPN: DM3501, Acris), followed by incubation with biotinylated-labelled secondary antibody (1:250, Vector Laboratories) for 45 min. ABC complex was then applied for 30 min and staining was completed by 3 min incubation with DAB and chromogen (SK 4100, Vector Laboratories). Slides were counterstained with haematoxylin and mounted. ER-TR7 staining was conducted on 10-mm-thick frozen lymph node sections (Santa Cruz, sc-73355-AF488). Gap analysis. Quantification of gap sizes was carried out in MATLAB. PDPN signal was isolated and converted to greyscale. The images were thresholded, background subtracted, small objects removed, then converted to binary images using ImageJ software. A circle-fitting algorithm was applied whereby, in each step, the largest circle that could fit in the gaps and that did not overlap with other fitted circles was recorded. The distribution of radii of circles that fill the image was then weighted according to area such that larger circles had a proportionally greater weighting than smaller circles. The plot of distribution of radii was smoothed to transform the data from a discrete pixel size distribution to a continuous micrometre-size distribution. Raw data were analysed using Fisher's exact test (P 5 4.194 3 10 29 ) to determine differences in circles with radius .15 mm. Each analysis was performed on images of the FRC network from .8 individual mice per group. No images were excluded from the analysis and all data were combined and are represented in the graphs shown (16 images per group). MATLAB script is available upon request. Automated morphometric analysis. The slides were digitized with a commercial image analysis system (Ariol; Leica Biosystems). The program was trained to recognize GFP 1 stained nuclei by size, shape and staining intensity. T-cell areas were identified by density of haematoxylin staining and traced out manually on each lymph node in the scan. Automated analysis then counted the total number of GFP 1 nuclei in each T-cell area (24 areas analysed per group). Area/FRC nuclei were compared using Mann-Whitney U-test. Rac1-GTP pulldown assay. FRC cell lines either treated with CLEC-2-Fc for 30 min or stably depleted of PDPN (shRNA) were subjected to Rac1 pulldown and analysis as per manufacturer's instructions (kit 16118 Pierce). Rac1 levels in pulldowns and whole lysate were compared by western blot. Three-dimensional cell culture and gel contraction assay. Control or PDPN knockdown FRCs were seeded at 10,000 per well in 150 ml collagen/matrigel matrix 8, 26, 28 . Gels were set at 37 uC for 30 min then covered with cell culture medium. In some wells, the following were added to both the gel mix and medium: 10 mg ml 21 CLEC-2-Fc, 10 mM ROCK inhibitor (Y27632) or 10 mg ml 21 anti-PDPN antibody (R&D, AF3244). Contraction of the gel at day 3 was quantified as the ratio of contracted gel/original area and plotted relative to control. Gels were stained with TRITClabelled phalloidin and DAPI for maximum length analysis (Imaris). The furthest points of each individual cell were measured in x,y,z coordinates and vectors calculated for comparison (Extended Data Fig. 5 ). Statistics. Sample size for in vivo experiments was determined by litter size as littermate controls were used in all comparisons. For in vitro experiments, all cells within the sample were scored and none excluded and experiments were repeated at least once to ensure reproducibility and adequate statistical power. Category data from overexpression studies were analysed using Fisher's exact test (R software). Changes to contraction and morphology were analysed using Mann-Whitney U-tests. Analysis of cell populations during a time course of immunization was conducted with one-way ANOVA and followed by Kruskall-Wallis multiple comparisons test. Comparison of lymph node size and cellularity between control and CD11c DCLEC-2 across different treatment groups was analysed using two-way ANOVA followed by multiple comparisons test between treatments and genotypes. Appropriate statistical tests were chosen for the data set following advice from a mathematician (R.P.J.). Chemical screen for cell contraction inhibitors was scored by an independent observer (A.J.F.) who was unbiased as to the predicted results.
